MedTrace Logo

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

NCT06880081 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-03-02

No results posted yet for this study

Summary

The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are:

* Is PN20 safe in these patients?
* Could these patients potentially benefit from PN20 treatment?

Participants will

* Receive one subcutaneous injection of PN20 according to weight;
* Visit the clinic for assessment.

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

DRUG

PN20 treatment

Three dose cohorts, single dose, subcutaneous injections

Sponsors & Collaborators

  • Chongqing Peg-Bio Biopharm Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lei Zhang · Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-07
Primary Completion
2026-02-27
Completion
2026-04-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06880081 on ClinicalTrials.gov